3D Medicines (HKSE:01244) Cyclically Adjusted PS Ratio: (As of Sep. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01244 3D Medicines Inc HKSE:01244
47 GF Score
Price HK$2.26
GF Value HK$3.09
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is 3D Medicines Cyclically Adjusted PS Ratio?

3D Medicines does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


3D Medicines  (HKSE:01244) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


3D Medicines Cyclically Adjusted PS Ratio Related Terms


3D Medicines Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for 3D Medicines's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3D Medicines Cyclically Adjusted PS Ratio Chart

3D Medicines Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

3D Medicines Semi-Annual Data
Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

HKSE:01244 vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, 3D Medicines's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3D Medicines Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where 3D Medicines's Cyclically Adjusted PS Ratio falls into.


HKSE:01244
47GF Score
3D Medicines Inc HKSE:01244
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

3D Medicines Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

3D Medicines does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Is 3D Medicines (HKSE:01244) Overvalued in 2026?

Based on GuruFocus' analysis, 3D Medicines stock appears to be undervalued. The current stock price of HK$2.26 is trading 26.9% below its estimated GF Value™ of HK$3.09. GuruFocus considers 3D Medicines to be Modestly Undervalued.

Key valuation signals for HKSE:01244:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: HK$3.09 vs. price of HK$2.26 (26.9% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the HKSE:01244 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


3D Medicines Business Description

Address No. 3 and No. 5, Laiyang Road, Shandong Province, Shinan District, Qingdao, CHN
3D Medicines Inc is an investment holding company. The company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products.It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China. Its commercialized product is Envita.
47GF Score

Get the complete analysis for HKSE:01244

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.26
Price
HK$3.09
GF Value